source
- Gilead and Merck provide HIV data; Dimension Capital announces $800M fundGilead and Merck’s HIV data: The duo will present more detailed results of the Phase 3 trials of their once-weekly oral HIV treatment regimen at AIDS 2026, one of the largest ...Endpoints · 8d ago↗ source
- Agios’ second shot at sickle cell disease falls shortAgios said it is dropping a next-generation sickle cell disease drug after lackluster results from a mid-stage trial. The drug, known as tebapivat, represented Agios’ second shot at the disease, an…Endpoints · 8d ago↗ source
- Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and recently saw one of them acquired by AI giant Anthropic.